Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Molecular Mechanisms of SGLT2 Inhibition in Diabetic Kidney Disease
NCT05507892Phase 2Active, not recruiting
- Sponsor
- University of Colorado Denver
- Start
- Oct 2022
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of canagliflozin in type 2 diabetes mellitus (T2DM), diabetic kidney disease (DKD), sponsored by University of Colorado Denver. Started Oct 2022; status: active, not recruiting.
02
Drugs
canagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)diabetic kidney disease (DKD)
Beyond the preview
Go deeper on NCT05507892.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05507892.